Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.69 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871851 | 0.90 | F10 (0.66) | F10KDR | |
| SCHEMBL3866213 | 0.88 | F10 (0.67) | F10KDRKDM4ENPC1ALDH1A1 | |
| SCHEMBL3866754 | 0.88 | F10 (0.89) | F10 | |
| SCHEMBL3862452 | 0.85 | F10 (0.89) | F10 | |
| SCHEMBL3868923 | 0.81 | F10 (0.90) | F10 | |
| SCHEMBL3874831 | 0.80 | KDR (0.51) | F10KDRKDM4EALDH1A1HPGD | |
| SCHEMBL1675864 | 0.79 | F10 (0.45) | F10 | |
| SCHEMBL4919695 | 0.79 | F10 (0.53) | F10 | |
| SCHEMBL3864953 | 0.78 | F10 (0.64) | F10 | |
| SCHEMBL4920922 | 0.77 | F10 (0.52) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558247-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-02-20 | — | — | EP | claimed |
| US-20050272740-A1 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-12-08 | — | — | US | claimed |
| CN-1674893-A | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-09-28 | — | — | CN | claimed |
| US-7566789-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| EP-1558247-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-02-20 | — | — | EP | disclosed |
| US-20050272740-A1 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| CN-1674893-A | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272740-A1 | Benzimidazole derivatives | F12, F11, SERPINC1 | F10 5/4885KDR 2792/4885KDM4E 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.